Compound: zalcitabine
SMILES: O=c1nc(N)ccn1[C@@H]2O[C@H](CO)CC2
InChIKey: WREGKURFCTUGRC-POYBYMJQSA-N
Synonyms: zalcitabine, Dideoxycytidine, 7481-89-2, 2',3'-DIDEOXYCYTIDINE, ddCyd, Cytidine, 2',3'-dideoxy-, 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, NSC 606170, Ro 24-2027/000, Ro-24-2027/000, zalcitabina, DTXSID0023747, 6L3XT8CB3I, NSC606170, 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one, Ro-242027000, DTXCID703747, Ro-24-2027000, CHEBI:10101, Zalcitabine (dideoxycytidine,ddc), 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, ddC (Antiviral), 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE, HIVID Roche, 2',3' Dideoxycytidine, zalcitabinum, 4-amino-1-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one, 4-amino-1-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)-1,2-dihydropyrimidin-2-one, RefChem:389367, J05AF03, 620-762-3, HIVID, ddC, MFCD00012188, NSC-606170, 2', 3'-dideoxycytidine, CHEMBL853, NCGC00090705-08, Zalcitibine, 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one, 2,3-dideoxycytidine, SMR000058253, CCRIS 692, Hivid(TM), Hivid (TN), HSDB 7156, ddC & GM-CSF, ddC & sCD4, PC-SOD & ddC, DDC (DDC), UNII-6L3XT8CB3I, BRN 0654956, Zalcitabine (JAN/USP/INN), Zalcitabine?, DS-4152 & ddC, 3-[(5S,2R)-5-(hydroxymethyl)oxolan-2-yl]-6-amino-3-hydropyrimidin-2-one, 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine, ddC & NP (from PHCA or HSA), SRI-7707, Zalcitabine [USAN:USP:INN:BAN], 2',3'-Dideoxycytidine;ddC;Dideoxycytidine, CAS-7481-89-2, KS-1130, ddC & IFN.alpha., .beta.-D-DDC, dideoxycytidine (DDC), Zalcitabine (Standard), ZALCITABINE [MI], Prestwick0_001037, Prestwick1_001037, Prestwick2_001037, Prestwick3_001037, ddC & Interferon.alpha., ZALCITABINE [INN], ZALCITABINE [JAN], ZALCITABINE [HSDB], ZALCITABINE [IARC], ZALCITABINE [USAN], bmse000712, UPCMLD-DP115, D 5782, ZALCITABINE [VANDF], SCHEMBL3598, TimTec1_004969, ZALCITABINE [MART.], 2',3'-Dideoxy-D-cytidine, Lopac0_000360, BSPBio_001253, ZALCITABINE [USP-RS], ZALCITABINE [WHO-DD], 5-25-14-00313 (Beilstein Handbook Reference), MLS000069636, MLS000759540, MLS001055363, MLS001424210, MLS006011951, SPBio_003104, BPBio1_001378, GTPL4828, orb1310928, 2',3'-ddC, SCHEMBL10378805, UPCMLD-DP115:001, Zalcitabine - Bio-X trade mark, 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein), ZALCITABINE [ORANGE BOOK], GLXC-06578, HMS1548B19, HMS1571O15, HMS2051H18, HMS2090C12, HMS2098O15, HMS2236N08, HMS3261G21, HMS3715O15, Pharmakon1600-01502360, ZALCITABINE [USP IMPURITY], .beta.-D-2',3'-Dideoxycytidine, Zalcitabine, 2'3'-Dideoxycytidine, Tox21_113491, Tox21_201655, Tox21_303169, Tox21_500360, AC-824, BDBM50145605, EBC-07537, HY-17392R, Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine, NSC759655, s1719, SBB066036, AKOS015854844, AKOS015894505, Tox21_113491_1, CCG-101050, CS-1110, DB00943, LP00360, NC00300, ND06559, NSC-759655, SDCCGSBI-0050348.P002, SRI-7707-13, SRI-7707-14, SRI-7707_15, SRI-7707_17, NCGC00090705-01, NCGC00090705-02, NCGC00090705-03, NCGC00090705-05, NCGC00090705-06, NCGC00090705-07, NCGC00090705-09, NCGC00090705-10, NCGC00090705-11, NCGC00090705-13, NCGC00090705-15, NCGC00090705-24, NCGC00090705-25, NCGC00179242-01, NCGC00257202-01, NCGC00259204-01, NCGC00261045-01, BD164564, BP-58631, HY-17392, ST069364, SY106119, ddC;Dideoxycytidine;2',3'-Dideoxycytidine, 2',3'-Dideoxycytidine & Interferon.alpha., 2',3'-Dideoxycytidine, >=98% (HPLC), DB-019728, D3581, EU-0100360, NS00005543, SW197364-4, Ro-24-2027-000, C07207, C76390, D00412, EN300-120633, Cytidine, 2',3'-dideoxy- & Interferon.alpha., F222318, SR-01000075822, SR-01000736919, ZALCITABINE (DIDEOXYCYTIDINE,DDC) [VANDF], Q2344582, SR-01000075822-1, SR-01000736919-5, BRD-K85925969-001-16-6, BRD-K85925969-001-17-4, Cytidine, 2',3'-dideoxy- & Colony-stimulating factor, Ro-242027000/Ro-24-2027-000, Z1550648753, Zalcitabine, United States Pharmacopeia (USP) Reference Standard, 2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxycytidine, 2 inverted exclamation marka,3 inverted exclamation marka-Dideoxycytidine, 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one, 4-Amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one, .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
Theoretical properties:
molecular_formula: C9H13N3O3
molecular_weight: 211.22 g/mol
exact_mass: 211.09569129 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 2
heavy_atom_count: 15
topological_polar_surface_area: 88.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from ethanol and benzene
color: Crystals from ethanol and benzene
melting_point: 410 to 417 °F (NTP, 1992)
solubility: 50 to 100 mg/mL at 66 °F (NTP, 1992)
vapor_pressure: 5.8X10-8 mm Hg @ 25 °C /Estimated/
Descriptions:
pubchem: Zalcitabine can cause cancer according to California Labor Code.
chebi: A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.
chembl: ZALCITABINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.
Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.